Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody
Viruses · 2023
DOI: 10.3390/v15071540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Ahmed M Khalil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Texas Biomedical Research Institute, San Antonio, TX 78245, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza A virus, Influenza Vaccines, Orthomyxoviridae Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Influenza B virus (IBV) contributes to substantial influenza-mediated morbidity and mortality, particularly among children. Similar to influenza A viruses (IAV), the hemagglutinin (HA) and neuraminidase (NA) of IBV undergo antigenic drift, necessitating regular reformulation of seasonal influenza vaccines. NA inhibitors, such as oseltamivir, have reduced activity and clinical efficacy against IBV, while M2 channel inhibitors are only effective against IAV, highlighting the need for improved vaccine and therapeutics for the treatment of seasonal IBV infections. We have previously described a potent human monoclonal antibody (hMAb), 1092D4, that is specific for IBV NA and neutralizes a broad range of IBVs. The anti-viral activity of MAbs can include direct mechanisms such as through neutralization and/or Fc-mediated effector functions that are dependent on accessory cells expressing Fc receptors and that could be impacted by potential host-dependent variability. To discern if the in vivo efficacy of 1092D4 was dependent on Fc-effector function, 1092D4 hMAb with reduced ability to bind to Fc receptors (1092D4–LALAPG) was generated and tested. 1092D4–LALAPG had comparable in vitro binding, neutralization, and inhibition of NA activity to 1092D4. 1092D4–LALAPG was effective at protecting against a lethal challenge of IBV in mice. These results suggest that hMAb 1092D4 in vivo activity is minimally dependent on Fc-effector functions, a characteristic that may extend to other hMAbs that have potent NA inhibition activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Texas Biomedical Research Institute, San Antonio, TX 78245, USA.
- Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.
- Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
ORCID-Profile: Ahmed M Khalil, Michael S Piepenbrink, Luis Martinez-Sobrido, James J Kobie
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- New York Influenza Center of Excellence (NYICE)
- Center for Research on Influenza Pathogenesis (CRIP)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Systems Biology Lens
Zitieren
APA
Khalil, A. M., Piepenbrink, M. S., Markham, I., Basu, M., Martinez-Sobrido, L., & Kobie, J. J. (2023). Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody. Viruses. https://doi.org/10.3390/v15071540
Vancouver
Khalil AM, Piepenbrink MS, Markham I, Basu M, Martinez-Sobrido L, Kobie JJ. Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody. Viruses. 2023. doi:10.3390/v15071540
BibTeX
@article{Khalil2023,
author = {Khalil, Ahmed M and Piepenbrink, Michael S and Markham, Ian and Basu, Madhubanti and Martinez-Sobrido, Luis and Kobie, James J},
title = {Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15071540}
}
EUVIMED